WO2003014329A3 - Modulation of angiogenesis by a-beta peptides - Google Patents

Modulation of angiogenesis by a-beta peptides Download PDF

Info

Publication number
WO2003014329A3
WO2003014329A3 PCT/US2002/027040 US0227040W WO03014329A3 WO 2003014329 A3 WO2003014329 A3 WO 2003014329A3 US 0227040 W US0227040 W US 0227040W WO 03014329 A3 WO03014329 A3 WO 03014329A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
diseases
kits
angiogenic
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/027040
Other languages
French (fr)
Other versions
WO2003014329A2 (en
Inventor
Daniel Paris
Michael Mullan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Priority to CA002467922A priority Critical patent/CA2467922A1/en
Priority to AU2002324787A priority patent/AU2002324787A1/en
Priority to EP02759452A priority patent/EP1424892A4/en
Publication of WO2003014329A2 publication Critical patent/WO2003014329A2/en
Anticipated expiration legal-status Critical
Publication of WO2003014329A3 publication Critical patent/WO2003014329A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)

Abstract

The present invention provides methods and compositions for treating diseases and pathological conditions or processes mediated by undesired and/or uncontrolled angiongenesis (characterized as 'angiogenic diseases') by increasing the in vivo concentration of the Aβ peptide, or biologically active fragments or variants of the Aβ peptide, within a patient suffering from such diseases, conditions, or processes. The present invention also concerns diagnostic methods and kits for detection and measurement of anti-angiogenic Aβ peptide activity in biological fluids and tissues. Such diagnostic methods and kits can be utilized to screen compounds for potential therapeutic activity in the treatment of Alzheimer's disease.
PCT/US2002/027040 2001-08-10 2002-08-12 Modulation of angiogenesis by a-beta peptides Ceased WO2003014329A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002467922A CA2467922A1 (en) 2001-08-10 2002-08-12 Modulation of angiogenesis by a-beta peptides
AU2002324787A AU2002324787A1 (en) 2001-08-10 2002-08-12 Modulation of angiogenesis by a-beta peptides
EP02759452A EP1424892A4 (en) 2001-08-10 2002-08-12 MODULATION OF ANGIOGENESIS BY A-BETA-PEPTIDE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31165601P 2001-08-10 2001-08-10
US60/311,656 2001-08-10

Publications (2)

Publication Number Publication Date
WO2003014329A2 WO2003014329A2 (en) 2003-02-20
WO2003014329A3 true WO2003014329A3 (en) 2004-02-12

Family

ID=23207880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027040 Ceased WO2003014329A2 (en) 2001-08-10 2002-08-12 Modulation of angiogenesis by a-beta peptides

Country Status (5)

Country Link
US (1) US7589168B2 (en)
EP (1) EP1424892A4 (en)
AU (1) AU2002324787A1 (en)
CA (1) CA2467922A1 (en)
WO (1) WO2003014329A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3910569B2 (en) * 2003-08-19 2007-04-25 独立行政法人科学技術振興機構 Reagent for amplifying amyloid fibrillation of amyloid β protein
EP1951750A4 (en) * 2005-11-10 2009-12-09 Roskamp Res Llc Modulation of angiogenesis by a-beta peptide fragments
PT1976877E (en) 2005-11-30 2014-04-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
WO2007064917A2 (en) * 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
JP5186632B2 (en) 2006-10-19 2013-04-17 ブリッタ ハーディ， Compositions and methods for inducing angiogenesis
HRP20160177T1 (en) * 2008-04-14 2016-03-25 Alzinova Ab STABLE AMYLOID BETA MONOMERS AND OLIGOMERS
CN105348387B (en) 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
US9890201B2 (en) 2013-08-02 2018-02-13 International Park Of Creativity Biological devices and methods of use thereof for the study and control of alzheimer's disease
GB201319656D0 (en) * 2013-11-07 2013-12-25 Univ Leuven Kath A yeast model for synergistic toxicity
CN118119846A (en) * 2021-07-16 2024-05-31 医疗财团法人徐元智先生医药基金会亚东纪念医院 Methods and kits for diagnosing mild cognitive impairment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARIS ET AL.: "Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway", NEUROBIOLOGY OF AGING, vol. 21, 2000, pages 183 - 197, XP001151845 *
See also references of EP1424892A4 *
TARKOWSKI ET AL.: "Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia", NEUROBIOLOGY OF AGING, vol. 23, 2002, pages 237 - 243, XP002969167 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO2003014329A2 (en) 2003-02-20
AU2002324787A1 (en) 2003-02-24
CA2467922A1 (en) 2003-02-20
EP1424892A2 (en) 2004-06-09
US20030077261A1 (en) 2003-04-24
US7589168B2 (en) 2009-09-15
EP1424892A4 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
EP2006298A3 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
ATE468137T1 (en) INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES
WO2002074240A3 (en) Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder
AU1922101A (en) Human fgf-21 gene and gene expression products
CA2403687A1 (en) Surgical articles
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
IS6170A (en) Substances for bereavement and treatment of amniotic fluid
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
SG49841A1 (en) Keratinocyte growth factor (kfg) for its use in method of therapeutic treatment for the human or animal body
WO2002050277A3 (en) Protein and nucleic acids encoding same
TR199903154T2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003048775A3 (en) Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
DE59310320D1 (en) New means of diagnosing vascular diseases
ATE337339T1 (en) THERAPEUTIC USE OF SMR1 PROTEIN AND ITS ACTIVE DERIVATIVES
SG121733A1 (en) Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
EA200200533A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE IN VIVO DELIVERY OF GENES
ATE374618T1 (en) USE OF RECOMBINANT HUMAN UTEROGLOBIN FOR THE TREATMENT OF FIBROTIC DISEASES
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
TNSN01076A1 (en) ASSOCIATIONS OF GROWTH HORMONE SECRETAGOGUES AND ANTIDEPRESSANTS, AND COMPOSITIONS CONTAINING THEM
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO2002046221A3 (en) Human protein differentially expressed in alzheimer's disease's brain
WO2002070696A3 (en) Cd109 nucleic acid molecules polypeptides and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002759452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467922

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002759452

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP